Comparing the current results to its competitors, Biovie Inc reported Revenue decrease in the 4 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 13.59 %, recorded in the same quarter.
Biovie Inc , slower than the average decrease reported by the company's competitors of -50.65 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -50.65 %
Biovie Inc 's Comment on Competition and Industry Peers
Orphan drug exclusivity provides a seven-year period during which competitors are prohibited from marketing the same drug or biological product for the same indication, regardless of patent status. Competitors may obtain approval for different products or for the same product used for different indications. The company holds multiple issued patents and pending applications protecting Bezisterim (NE3107) and related compounds. The FDA's Fast Track program is designed to expedite the review of new drugs and biological products that meet specific criteria.
September 16, 2024
In a significant development for the pharmaceutical landscape, BioVie, a clinical-stage company focused on advancing innovative therapies, has recently announced the successful acquisition of all necessary scientific approvals requisite for the large-scale financing of its pivotal Phase 2 clinical trial for Bezisterim. This trial aims to investigate the efficacy of Bezisterim in treating Long COVID, a condition characterized by lingering symptoms that affect a significant portion of patients recovering from COVID-19.The critical green light came from the U.S. Army Medical Research and Development Command’s Office of Human Research Oversight, representing the final scientific milestone for BioVie to secure ...
September 3, 2024
BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID Authorization expands use of bezisterim in a Phase 2, placebo-controlled, multicenter trial assessing bezisterim s impact on neurological symptoms associated with long COVID The biopharmaceutical landscape has been abuzz with recent developments, and a notable highlight is BioVie Inc. s announcement regarding the FDA’s authorization of their Investigational New Drug (IND) application. This approval heralds the initiation of a Phase 2 clinical trial targeting a pressing and somewhat enigmatic condition: long COVID.Long COVID, characterized by persistent symptoms following the ac...
March 15, 2024
In recent developments, renowned law firm Hagens Berman has issued an alert to BioVie Inc. (NASDAQ: BIVI) investors who have experienced significant financial losses. The firm urges affected investors to come forward and submit their losses before the approaching March 19th deadline. This article aims to provide an overview of the situation based on the available information.Background:BioVie Inc., a pharmaceutical company known for its research and development in innovative therapies, has attracted the attention of Hagens Berman. The law firm is concerned about potential substantial losses investors may have suffered and is actively seeking to uncover any unlawful practices that may have contributed to the...
March 11, 2024
BioVie, a leading pharmaceutical company focused on developing innovative therapies for life-threatening neurological diseases, has made significant strides in its pipeline progress. With a recent financing, the company is now well-funded to prioritize its near-term clinical efforts, particularly in addressing Parkinson s Disease (PD). This article presents an update on BioVie s pipeline and highlights the company s intelligent approach to tackling this debilitating neurological disorder.Pipeline Progress: BioVie has maintained a steadfast commitment to advancing its drug candidates, particularly as they pertain to PD. The recently completed financing has infused the company with sufficient funds, empowering...
An2 Therapeutics Inc is a biotechnology company that develops therapeutics for the treatment of rare diseases. Their business model focuses on research and development of innovative drugs that target specific genetic mutations responsible for these rare conditions, aiming to provide effective and personalized treatments. By collaborating with pharmaceutical partners and leveraging their expertise in drug discovery, An2 Therapeutics Inc aims to bring their therapies to market and improve the lives of patients with rare diseases.
Xoma Corporation operates under a business model focused on the development and commercialization of novel therapeutics. The company primarily concentrates on creating antibody-based therapies to address unmet medical needs. Xoma also engages in collaborations and partnerships with other pharmaceutical companies to advance their product pipeline and expand their reach in the market.
Bicycle Therapeutics Plc's business model is centered around the development and commercialization of novel therapeutics using its proprietary bicyclic peptide platform.
Tenax Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing products for critical care patients with cardiovascular and pulmonary diseases. Their business model revolves around conducting research and clinical trials to bring innovative therapies to market. They generate revenue primarily by licensing their products to other pharmaceutical companies or through direct sales to hospitals and healthcare providers.
Sources:
Biovie Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biovie Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
